Trials / Completed
CompletedNCT00699764
Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease
Safety of SmithKline Beecham Biologicals' Herpes Simplex Candidate Vaccine (gD2t) With MPL & Its Efficacy to Prevent Genital Herpes Disease in HSV Positive or Negative Consorts of Subjects With Genital Herpes Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,491 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate the safety of Herpes Simplex candidate vaccine (gD2t) with adjuvant and its efficacy to prevent genital herpes disease in HSV positive or negative consorts of subjects with genital herpes disease.
Detailed description
This study was monitored by a Data Safety Monitoring Board At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Herpes simplex candidate vaccine- adjuvanted GSK208141 | Intramuscular injection, 3 doses |
| BIOLOGICAL | Placebo injection | Intramuscular injection, 3 doses |
Timeline
- Start date
- 1996-03-01
- Primary completion
- 1999-10-01
- Completion
- 1999-10-01
- First posted
- 2008-06-18
- Last updated
- 2016-09-07
Source: ClinicalTrials.gov record NCT00699764. Inclusion in this directory is not an endorsement.